Charles River Laboratories has acquired Oncotest GmbH, a Germany-based CRO providing target discovery and validation services for preclinical oncology research, for approximately $36 million in cash. The transaction also includes a potential additional payment of $2 million based on future performance. The company specializes in in vivo pharmacology services with a collection of more than 400 patient-derived xenograft (PDX) tumor models, as well as in vitro assays using both commercially availab...